Professor Ewan Cameron

Deputy Head of College of MVLS / Professor of Molecular and Cellular Oncology (Veterinary Pathology, Public Health & Disease Investigation)

telephone: 01413305701
email: Ewan.Cameron@glasgow.ac.uk
pronouns: He/him/his

R333 Level 3, Large Animal Clinical Sci & PH, Henry Wellcome ICM, Glasgow G61 1BD

Personal assistant: Mrs Julie Norden
telephone: 01413305702
email: Julie.Norden@glasgow.ac.uk

Biography

Ewan Cameron served as Head of the School of Veterinary Medicine between 2010 - 2022 and led the merger with the Institute of Biodiversity Animal Health & Comparative Medicine to create the new School of Biodiversity, One Health & Veterinary Medicine in 2022. In 2023 he was appointed as Deputy Head of the College of Medical, Veterinary & Life Sciences, one of the four University Colleges.

He has interests in cancer biology, animal health, veterinary education and professional training. He graduated from the Faculty of Veterinary Medicine at the University of Glasgow in 1984 and after two years in veterinary practice he returned to the University to undertake postgraduate studies in the then relatively new field of transgenic biology. With funding from the Leukaemia Research Fund, he established a research group focussed on modelling multiple events in leukaemia development and was Co-Director of the Molecular Oncology Laboratory from 1996 to 2017, supported by a rolling series of programme grants. He was appointed Professor in Molecular and Cellular Oncology in 2004 and in the same year accepted the role of Deputy Dean, Faculty of Veterinary Medicine.

He has served as a member of Council of the Royal College of Veterinary Surgeons (RCVS) and a member of the Education Committee of the RCVS. He has also served on the American Association of Veterinary Medical Colleges (AAVMC) Board of Directors and as a member of the Executive Committee of the European Association of Establishments for Veterinary Education (EAEVE). He is a past chair of the Veterinary Schools Council of the UK, Ireland and the Netherlands.

Research interests

I have a long-standing interest in the function of the Runx genes and their role in various diseases. These genes act as transcription factors that regulate the expression of numerous other genes that have key roles in lineage development and cell fate decisions. The study of Runx gene function has relied heavily on the development and characterisation of models designed to address fundamental questions in biology, especially in the areas of oncology and cardiovascular disease.

For over 20 years I co-directed the Molecular Oncology Laboratory funded by joint programme grants from the Leukaemia Research Fund and Cancer Research UK. During this time, we sought to identify novel oncogenes that could contribute to the pathogenesis of leukaemia. This work led to a better understanding of oncogenic synergy and the discovery that Runx gene family members (also known as Core Binding Factors) could act as dominant oncogenes in blood cell cancers.

In subsequent work we went on to explore the role of the Runx family in solid tumours, especially breast cancer. Using a variety of model systems we have shown that depending on the context, the cancer subtype, and the nature of the collaborating oncogenic events, members of the Runx family can exert either a tumour suppressor or a pro-oncogenic function.

We have also explored these genes in the context of cardiovascular disease. Although not expressed at significant levels in healthy myocardium, members of the gene family are switched on following insult or injury to the heart. Runx function appears to have an important role in both of the two major forms of heart failure; those cases caused by damage to cardiac muscle resulting in reduced contractility and capacity to eject blood (systolic heart failure) and those resulting from metabolic disorders and other co-morbidities leading to reduced ventricle relaxation and filling (diastolic heart failure). In both conditions Runx activity mediates the adverse pathological changes that can ultimately lead to heart failure. Our current work, supported by a British Heart Foundation (BHF) programme grant, is based on understanding how blocking Runx activity prevents disease progression and exploring the therapeutic opportunities arising from our findings.

Publications

List by: Type | Date

Jump to: 2023 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1990

Number of items: 65.

2023

Martin, T. P. et al. (2023) Ribonucleicacid interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction. Cardiovascular Research, 119(16), 2663–2671-2663–2671. (doi: 10.1093/cvr/cvad107) (PMID:37433039) (PMCID:PMC10730241)

Khan, A. S., Campbell, K. J., Cameron, E. R. and Blyth, K. (2023) The RUNX/CBFβ complex in breast cancer: a conundrum of context. Cells, 12(4), 641. (doi: 10.3390/cells12040641) (PMID:36831308) (PMCID:PMC9953914)

2020

Armando, F. et al. (2020) Endocanalicular transendothelial crossing (ETC): a novel intravasation mode used by HEK-EBNA293-VEGF-D cells during the metastatic process in a xenograft model. PLoS ONE, 15(10), e0239932. (doi: 10.1371/journal.pone.0239932) (PMID:33085676) (PMCID:PMC7577447)

Riddell, A. , McBride, M. , Braun, T., Nicklin, S. A. , Cameron, E. , Loughrey, C. M. and Martin, T. P. (2020) RUNX1: an emerging therapeutic target for cardiovascular disease. Cardiovascular Research, 116(8), pp. 1410-1423. (doi: 10.1093/cvr/cvaa034) (PMID:32154891) (PMCID:PMC7314639)

Rooney, N. et al. (2020) RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Research, 80(11), pp. 2325-2339. (doi: 10.1158/0008-5472.CAN-19-3870) (PMID:32156779)

Sweeney, K., Cameron, E. R. and Blyth, K. (2020) Complex interplay between the RUNX transcription factors and Wnt/β-catenin pathway in cancer: a tango in the night. Molecules and Cells, 43(2), pp. 188-197. (doi: 10.14348/molcells.2019.0310) (PMID:32041394) (PMCID:PMC7057843)

2019

Loyola, L. et al. (2019) Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. PLoS Pathogens, 15(12), e1008154. (doi: 10.1371/journal.ppat.1008154) (PMID:31815961) (PMCID:PMC6974304)

Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)

2018

Anderson, G. et al. (2018) RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. Journal of Cellular Biochemistry, 119(3), pp. 2750-2762. (doi: 10.1002/jcb.26443) (PMID:29052866) (PMCID:PMC5813226)

McCarroll, C. S. et al. (2018) Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation, 137(1), pp. 57-70. (doi: 10.1161/CIRCULATIONAHA.117.028911) (PMID:29030345) (PMCID:PMC5757664)

2017

Kilbey, A. et al. (2017) Runx1 orchestrates sphingolipid metabolism and glucocorticoid resistance in lymphomagenesis. Journal of Cellular Biochemistry, 118(6), pp. 1432-1441. (doi: 10.1002/jcb.25802) (PMID:27869314) (PMCID:PMC5408393)

Rooney, N., Riggio, A. I., Mendoza-Villanueva, D., Shore, P., Cameron, E. R. and Blyth, K. (2017) Runx genes in breast cancer and the mammary lineage. In: Groner, Y., Ito, Y., Liu, P., Neil, J. C., Speck, N. A. and van Wijnen, A. (eds.) RUNX Proteins in Development and Cancer. Series: Advances in experimental medicine and biology, 96 (962). Springer, pp. 353-368. ISBN 9789811032318 (doi: 10.1007/978-981-10-3233-2_22)

Terry, A., Kilbey, A., Naseer, A., Levy, L. S., Ahmad, S., Watts, C., Mackay, N., Cameron, E. , Wilson, S. and Neil, J. C. (2017) Barriers to infection of human cells by feline leukemia virus: insights into resistance to zoonosis. Journal of Virology, 91(5), e02119-16. (doi: 10.1128/JVI.02119-16) (PMID:28031367) (PMCID:PMC5309941)

2016

Gilroy, K. L. et al. (2016) Gamma-retrovirus integration marks cell type-specific cancer genes: a novel profiling tool in cancer genomics. PLoS ONE, 11(4), e0154070. (doi: 10.1371/journal.pone.0154070) (PMID:27097319) (PMCID:PMC4838236)

Borland, G. et al. (2016) Addiction to Runx1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model. Oncotarget, 7(17), pp. 22973-22987. (doi: 10.18632/oncotarget.8554) (PMID:27056890) (PMCID:PMC5029604)

2015

Naseer, A. et al. (2015) Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo. Viruses, 7(4), pp. 2014-2029. (doi: 10.3390/v7042014) (PMID:25912714) (PMCID:PMC4411688)

Ferrari, N. et al. (2015) Runx2 contributes to the regenerative potential of the mammary epithelium. Scientific Reports, 5, 15658. (doi: 10.1038/srep15658) (PMID:26489514) (PMCID:PMC4614940)

2014

Ferrari, N., Mohammed, Z. M. A., Nixon, C., Mason, S. M., Mallon, E., McMillan, D. C. , Morris, J. S. , Cameron, E. R. , Edwards, J. and Blyth, K. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS ONE, 9(6), e100759. (doi: 10.1371/journal.pone.0100759) (PMID:24967588) (PMCID:PMC4072705)

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

Huser, C. A. et al. (2014) Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis. PLoS Genetics, 10(2), e1004167. (doi: 10.1371/journal.pgen.1004167) (PMID:24586197) (PMCID:PMC3937229)

2013

Ferrari, N., McDonald, L., Morris, J.S. , Cameron, E.R. and Blyth, K. (2013) RUNX2 in mammary gland development and breast cancer. Journal of Cellular Physiology, 228(6), pp. 1137-1142. (doi: 10.1002/jcp.24285)

2011

Emons, J. et al. (2011) Genome-wide screening in human growth plates during puberty in one patient suggests a role for RUNX2 in epiphyseal maturation. Journal of Endocrinology, 209(2), pp. 245-254. (doi: 10.1530/JOE-10-0219)

Cameron, E. (2011) Celebrating 150 years of Glasgow Vet School. Veterinary Record, 169(10), p. 262. (doi: 10.1136/vr.d5550)

2010

Blyth, K. , Vaillant, F., Jenkins, A., McDonald, L., Pringle, M. A. , Huser, C. , Stein, T. , Neil, J. and Cameron, E. R. (2010) Runx2 in normal tissues and cancer cells: A developing story. Blood Cells, Molecules, and Diseases, 45(2), pp. 117-123. (doi: 10.1016/j.bcmd.2010.05.007)

Kilbey, A., Terry, A., Jenkins, A., Borland, G., Zhang, Q.F., Wakelam, M.J.O., Cameron, E.R. and Neil, J.C. (2010) Runx regulation of sphingolipid metabolism and survival signaling. Cancer Research, 70(14), pp. 5860-5869. (doi: 10.1158/0008-5472.CAN-10-0726)

2009

Blyth, K. , Slater, N., Hanlon, L., Bell, M., Mackay, N., Stewart, M., Neil, J.C. and Cameron, E.R. (2009) Runx1 promotes B-cell survival and lymphoma development. Blood Cells, Molecules, and Diseases, 43(1), pp. 12-19. (doi: 10.1016/j.bcmd.2009.01.013)

Wolyniec, K., Wotton, S., Kilbey, A., Jenkins, A., Terry, A., Peters, G., Stocking, C., Cameron, E.R. and Neil, J.C. (2009) RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene, 28(27), pp. 2502-2512. (doi: 10.1038/onc.2009.101)

Scobie, L. et al. (2009) A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Molecular Therapy, 17(6), pp. 1031-1038. (doi: 10.1038/mt.2009.59)

2008

Wotton, S., Terry, A., Kilbey, A., Jenkins, A., Herzyk, P. , Cameron, E. and Neil, J.C. (2008) Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene, 27(44), pp. 5856-5866. (doi: 10.1038/onc.2008.195)

Kilbey, A., Terry, A., Cameron, E.R. and Neil, J.C. (2008) Oncogene-induced senescence: an essential role for Runx. Cell Cycle, 7(15), pp. 2333-2340.

2007

Stewart, M., Mackay, N., Hanlon, L., Blyth, K. , Scobie, L., Cameron, E. and Neil, J. (2007) Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Research, 67(11), pp. 5126-5133. (doi: 10.1158/0008-5472.CAN-07-0433) (PMID:17545590) (PMCID:PMC2562448)

Kilbey, A., Blyth, K. , Wotton, S., Terry, A., Jenkins, A., Bell, M., Hanlon, L., Cameron, E.R. and Neil, J.C. (2007) Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Research, 67(23), pp. 11263-11271. (doi: 10.1158/0008-5472.CAN-07-3016)

2006

Blyth, K. , Vaillant, F., Hanlon, L., Mackay, N., Bell, M., Jenkins, A., Neil, J.C. and Cameron, E.R. (2006) Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Research, 66(4), pp. 2195-2201. (doi: 10.1158/0008-5472.CAN-05-3558) (PMID:16489021)

Thrasher, A.J. et al. (2006) Gene therapy: X-SCID transgene leukaemogenicity. Nature, 443(7109), E5-E6. (doi: 10.1038/nature05219)

2005

Blyth, K. , Cameron, E.R. and Neil, J.C. (2005) The RUNX genes: gain or loss of function in cancer. Nature Reviews Cancer, 5(5), pp. 376-387. (doi: 10.1038/nrc1607) (PMID:15864279)

2004

Wotton, S. F., Blyth, K. , Kilbey, A., Jenkins, A., Terry, A., Bernardin-Fried, F., Friedman, A. D., Baxter, E. W., Neil, J. C. and Cameron, E. R. (2004) RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene, 23(32), pp. 5476-5486. (doi: 10.1038/sj.onc.1207729) (PMID:15133495)

Barber, K.E. et al. (2004) Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia, 18(6), pp. 1153-1156. (doi: 10.1038/sj.leu.2403357) (PMID:15057249)

Cameron, E. and Neil, J. (2004) The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene, 23, pp. 4308-4314. (doi: 10.1038/sj.onc.1207130)

Terry, A., Kilbey, A., Vaillant, F., Stewart, M., Jenkins, A., Cameron, E. and Neil, J. (2004) Conservation and expression of an alternative 3 ' exon of Runx2 encoding a novel proline-rich C-terminal domain. Gene, 336, pp. 115-125. (doi: 10.1016/j.gene.2004.04.015)

2003

Cameron, E. R., Blyth, K. , Hanlon, L., Kilbey, A., Mackay, N., Stewart, M., Terry, A., Vaillant, F., Wotton, S. and Neil, J. C. (2003) The Runx genes as dominant oncogenes. Blood Cells, Molecules, and Diseases, 30, pp. 194-200. (doi: 10.1016/S1079-9796(03)00031-7)

Hanlon, L., Barr, N.I., Blyth, K. , Stewart, M., Haviernik, P., Wolff, L., Weston, K., Cameron, E.R. and Neil, J.C. (2003) Long-range effects of retroviral insertion on c-myb: Overexpression may be obscured by silencing during tumor growth in vitro. Journal of Virology, 77(2), pp. 1059-1068. (doi: 10.1128/JVI.77.2.1059-1068.2003) (PMID:12502821) (PMCID:PMC140821)

2002

Wotton, S., Stewart, M., Blyth, K. , Vaillant, F., Kilbey, A., Neil, J. C. and Cameron, E. R. (2002) Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Research, 62(24), pp. 7181-7185. (PMID:12499254)

Vaillant, F., Blyth, K. , Andrew, L., Neil, J. C. and Cameron, E. R. (2002) Enforced expression of Runx2 perturbs T cell development at a stage coincident with β-selection. Journal of Immunology, 169(6), pp. 2866-2874. (doi: 10.4049/jimmunol.169.6.2866)

Beatty, J., Terry, A., MacDonald, J., Gault, E., Cevario, S., OBrien, S., Cameron, E. and Neil, J. (2002) Feline immunodeficiency virus integration in B-cell lymphoma identifies a candidate tumor suppressor gene on human chromosome 15q15. Cancer Research, 62, pp. 7175-7180.

Neil, J. and Cameron, E. (2002) Retroviral insertion sites and cancer: Fountain of all knowledge? Cancer Cell, 2, pp. 253-255.

Stewart, M., MacKay, N., Cameron, E. and Neil, J. (2002) The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. Journal of Virology, 76(9), pp. 4364-4369. (doi: 10.1128/JVI.76.9.4364-4369.2002)

2001

Baxter, E. W., Blyth, K. , Cameron, E. R. and Neil, J. C. (2001) Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice. Journal of Virology, 75(20), pp. 9790-9798. (doi: 10.1128/JVI.75.20.9790-9798.2001) (PMID:11559812) (PMCID:PMC114551)

Ayers, E., Cameron, E. , Kemp, R., Leitch, H., Mollison, A., Muir, I., Reid, H., Smith, D. and Sproat, J. (2001) Oral lesions in sheep and cattle in Dumfries and Galloway. Veterinary Record, 148(23), pp. 720-723. (doi: 10.1136/vr.148.23.714)

Blyth, K. , Terry, A., Mackay, N., Vaillant, F., Bell, M., Cameron, E.R. , Neil, J.C. and Stewart, M. (2001) Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 20(3), pp. 295-302. (doi: 10.1038/sj.onc.1204090) (PMID:11313958)

2000

Blyth, K. , Stewart, M., Bell, M., James, C., Evan, G., Neil, J. C. and Cameron, E. R. (2000) Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene, 19(6), pp. 773-782. (doi: 10.1038/sj.onc.1203321) (PMID:10698495)

Cameron, E.R. , Morton, J. , Johnston, C.J., Irvine, J., Bell, M., Onions, D.E., Neil, J.C. , Campbell, M. and Blyth, K. (2000) Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene. Cell Death and Differentiation, 7(1), pp. 80-88. (doi: 10.1038/sj.cdd.4400630) (PMID:10713723)

1999

Vaillant, F., Blyth, K. , Terry, A., Bell, M., Cameron, E. R. , Neil, J. and Stewart, M. (1999) A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene, 18(50), pp. 7124-7134. (doi: 10.1038/sj.onc.1203202) (PMID:10597314)

Neil, J. , Stewart, M., Terry, A., O'Hara, M., Hu, M., Blyth, K. , Baxter, E., Onions, D. and Cameron, E. (1999) Identification of murine CBF alpha1, a runt domain transcription factor, as a putative Myc collaborator in T cell lymphoma. Leukemia, 13(S1), S83-S86. (doi: 10.1038/sj.leu.2401295) (PMID:10232373)

1998

Hall, A. P., Irvine, J., Blyth, K. , Cameron, E. R. , Onions, D. E. and Campbell, M. E.M. (1998) Tumours derived from HTLV-I tax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. Journal of Pathology, 186(2), pp. 209-214. (doi: 10.1002/(SICI)1096-9896(1998100)186:2<209::AID-PATH162>3.0.CO;2-I) (PMID:9924438)

1997

Webster, G., Onions, D.E., Neil, J.C. and Cameron, E.R. (1997) Skewed TCR Vbeta 8.2 usage in transgenic CD2-myc induced thymic lymphoma: a role for antigen stimulation in tumour development. British Journal of Cancer, 76(6), pp. 739-746. (doi: 10.1038/bjc.1997.455) (PMID:9310239) (PMCID:PMC2228037)

Stewart, M., Terry, A., Hu, M., O'Hara, M., Blyth, K. , Baxter, E., Cameron, E. , Onions, D.E. and Neil, J.C. (1997) Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proceedings of the National Academy of Sciences of the United States of America, 94(16), pp. 8646-8651. (doi: 10.1073/pnas.94.16.8646) (PMID:9238031) (PMCID:PMC23059)

Cameron, E. R. (1997) Recent advances in transgenic technology. Molecular Biotechnology, 7(3), pp. 253-265. (doi: 10.1007/BF02740816) (PMID:9219239)

Neil, J. C. , Cameron, E. R. and Baxter, E. W. (1997) p53 and tumour viruses: catching the guardian off-guard. Trends in Microbiology, 5(3), pp. 115-120. (doi: 10.1016/S0966-842X(96)10083-4) (PMID:9080610)

1996

Baxter, E.W., Blyth, K. , Donehower, L., Cameron, E.R. , Onions, D.E. and Neil, J.C. (1996) Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? Journal of Virology, 70(4), pp. 2095-100. (PMID:8642629) (PMCID:PMC190045)

Stewart, M., Terry, A., O'Hara, M., Cameron, E. , Onions, D. and Neil, J.C. (1996) til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. Journal of General Virology, 77(3), pp. 443-446. (doi: 10.1099/0022-1317-77-3-443) (PMID:8601779)

Cameron, E.R. , Campbell, M., Blyth, K. , Argyle, S.A., Keanie, L., Neil, J.C. and Onions, D.E. (1996) Apparent bypass of negative selection in CD8+ tumours in CD2-myc transgenic mice. British Journal of Cancer, 73(1), pp. 13-17. (doi: 10.1038/bjc.1996.3) (PMID:8554976) (PMCID:PMC2074291)

1995

Blyth, K. , Terry, A., O'Hara, M., Baxter, E.W., Campbell, M., Stewart, M., Donehower, L.A., Onions, D.E., Neil, J.C. and Cameron, E.R. (1995) Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene, 10(9), pp. 1717-1723. (PMID:7753548)

Hettle, S. J.H., Cameron, E. R. , Johnstone, C. S., Harvey, M. J.A. and Onions, D. E. (1995) Plasmids containing a murine autonomous replicating sequence in transgenic mice: function as an origin of replication, but inability to persist in an episomal state. Transgenics, 1(6), pp. 663-670.

1994

Cameron, E.R. , Harvey, M.J.A. and Onions, D.E. (1994) Transgenic science. British Veterinary Journal, 150(1), pp. 9-24. (doi: 10.1016/S0007-1935(05)80093-4) (PMID:8025841)

1990

Harvey, M., Hettle, S., Cameron, E. , Johnstone, C. and Onions, D. (1990) Production of transgenic lamb foetuses by sub-zonal injection of feline leukaemia virus. In: Church, R. B. (ed.) Transgenic Models in Medicine in Agriculture: Proceedings of a UCLA Symposium Held at Taos, New Mexico, January 28-February 3, 1989. Wiley-Liss: New York. ISBN 9780471567806

This list was generated on Mon Jan 20 19:10:31 2025 GMT.

Jump to: Articles | Book Sections